Novo Nordisk's annual financial reports

Novo Nordisk's Ozempic Reduces Deaths by 20% in FLOW Trial for Diabetes and Kidney Disease

May 24, 2024, 02:15 PM

Novo Nordisk's diabetes drug Ozempic has shown significant benefits in reducing risks for patients with type 2 diabetes and chronic kidney disease, according to new data from the FLOW Trial. The study revealed that Ozempic cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Additionally, the drug reduced the risk of major kidney disease events by 24% and slowed the progression of diabetic kidney disease. Over three years, treating 39 people would be needed to see these benefits. These findings suggest that Ozempic could transform the treatment landscape for patients suffering from these conditions.